GlassScriptPhysician profile
Bruce B Dershaw
NPI 1336188853
$8,240.83
in general payments reported to CMS, 2019-2025
39 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $1,248 · 2021: $475 · 2022: $496 · 2023: $1,362 · 2024: $1,030 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,277.94 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,714.58 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $516.24 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $512.84 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $394.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.10 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $266.99 | 2019-2025 | Brinsupri, Arikayce |
| Genentech USA, INC. | $246.82 | 2019-2024 | Xolair |
| Mylan Specialty L.P. | $193.40 | 2019-2024 | Yupelri |
| Philips North America LLC | $166.85 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $151.92 | 2019-2024 | |
| Verona Pharma, INC. | $142.37 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $137.87 | 2024-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $135.84 | 2019-2023 | Uptravi, Opsumit |
| Amgen INC. | $102.76 | 2023-2025 | Tezspire |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $101.27 | 2019-2020 | |
| Inogen, INC. | $66.29 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vifor Pharma, INC. | $66.07 | 2024-2025 | Zemaira |
| Harmony Biosciences LLC | $65.47 | 2020-2024 | |
| Axsome Therapeutics, INC. | $57.53 | 2023-2024 | Sunosi |
| Merck Sharp & Dohme LLC | $49.08 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.83 | 2022-2023 | Aralast |
| United Therapeutics Corporation | $44.38 | 2025 | Tyvaso |
| Electromed, INC. | $38.04 | 2025 | Smartvest |
| Pulmonx Corporation | $35.04 | 2022-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Teva Pharmaceuticals USA, INC. | $34.46 | 2019-2020 | |
| Circassia INC. | $28.77 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.57 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $28.30 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $27.91 | 2025 | Prolastin-C Liquid |
| Eisai INC. | $26.10 | 2020 | |
| Advanced Respiratory, INC | $25.95 | 2019-2020 | |
| Baxter Healthcare | $25.02 | 2024 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $19.06 | 2025 | Inspire |
| Lilly USA, LLC | $18.76 | 2025 | Zepbound |
| Viatris Specialty LLC | $15.47 | 2025 | Yupelri |
| Kaleo, INC. | $15.34 | 2019 | |
| Atricure, INC. | $14.91 | 2019 | |
| Resmed Corp | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Dershaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.